WRAPT
Weight Reduction in Asthma Programme with Tirzepatide (WRAPT): clinical efficacy and mechanisms of action
Chief Investigator:
Professor Andrew Wilson
Sponsor:
Norfolk and Norwich University Hospitals NHS Foundation Trust
Health Condition or Problem Studied:
Asthma with obesity
Study Design:
WRAPT is an interventional clinical trial of an investigational medicinal product: a phase IIb, randomised, placebo-controlled, two arm parallel group, double-blind, multicentre clinical trial. Randomisation will be generated by a secure web-based system on a 1:1 basis with stratification for recruiting location and type II inflammation (Y/N).
ACTIVE ARM:
Tirzepatide 15mg subcutaneous injection once weekly for 32 weeks following a dose up-titration from 2.5mg weekly every four weeks over a 20-week duration.
Or
CONTROL ARM:
Control saline injection, which appears identical to tirzepatide, once weekly.
Both groups will receive individual counselling every 4 weeks for the duration of the study, this will include dietary support and encouragement to increase their physical activity to 150 minutes of moderate activity (such as walking) per week.
Target Sample Size:
138 participants (69 per group)
Status:
In set-up
Contact details: